A new collaboration between Brookhaven National Laboratory and Best Medical International (BMI) aims to design one of the most dynamic and effective cancer therapy devices in the world. The ion Rapidly Cycling Medical Synchrotron (iRCMS) draws on the particle acceleration expertise of Brookhaven Laboratory physicists and the medical experience of BMI to advance cancer therapy, particularly the evolving use of carbon and other light ions.
Providing high-bandwidth communications for troops in remote forward operating locations is not only critical but also challenging because a reliable infrastructure optimized for remote geographic areas does not exist. DARPA recently announced the Fixed Wireless at a Distance program seeks to tackle the problem of stationary infrastructure designed specifically to overcome the challenge inherent with cell communication in remote areas.
Currently being developed by DARPA researchers at Washington-based Innovega iOptiks are contact lenses that enhance normal vision by allowing a wearer to view virtual and augmented reality images without the need for bulky apparatus.
The pharmaceutical industry won approval to market a record number of new drugs for rare diseases last year, as a combination of scientific innovation and business opportunity spurred new treatments for diseases long-ignored by drug companies. Many of these so-called orphan drugs offer extra patent protections and faster government approval.
How can you be sure that an incoming phone call is really from a customer and not an overseas criminal intent on fraud? For major financial services companies, that's a growing concern as the telephone system adopts Internet technologies—and the security issues that come with them. A startup company based on technology developed at Georgia Tech offers a solution to that challenge.
After two laboratories reported created new, easier-to-spread version of the deadly bird flu viruses, research was temporarily halted on Jan. 20. The pause comes as fierce debate intensifies over how to handle this high-risk research.
Through a draft Funding Opportunity Announcement (FOA) announced Friday, the U.S> Department of Energy plans to establish cost-shared agreements with private industry to support the design and licensing of small modular nuclear reactors (SMRs). About one-third the size of current nuclear plants, SMR are expected to both safer and cheaper to build and operate.
The Georgia Tech Research Institute has received a $1.5 million contract to produce an online environment that would let multiple design teams work together to develop new military vehicles. The VehicleForge project's goal is to create a secure central Website and other Web-based tools and methods that would facilitate such collaborative development.
Ariel Pharmaceuticals, a private, development-stage pharmaceutical company focused on the development and commercialization of products for indications in acute central nervous system diseases and trauma, announced it has signed a cooperative research and development agreement (CRADA) with the United States Army Medical Research and Material Command.
A new study by Rice University's Baker Institute for Public Policy illustrates a disconnect between government funding of biomedical research by young investigators and a novel standard by which to judge it: The Nobel Prize.
The 2012 R&D Magazine/Battelle Global R&D Funding Forecast is a comprehensive analysis of the state of industrial research worldwide. The report includes sections on R&D spending, globalization, the stable growth of the U.S., federal funding, industrial R&D, basic research, China's R&D momentum, Asia's R&D momentum, European research keeping pace, and more.
As 2012 approaches, U.S. investment in research has stabilized, but growth still lags previous years as a result of the sluggish economy. Given the current federal budget situation and announcements by a number of high-profile corporations regarding planned reductions in R&D spending, the stable, slow-growth trajectory that developed in 2011 will likely continue through 2012.
We estimate that federal R&D funding will reach $140.9 billion in FY 2012, a decline of 1.8% from our estimate of actual FY 2011 R&D funding ($143.5 billion) and 4.7% lower than the administration's FY 2012 R&D funding request.
In the next sections we examine, through survey and secondary data, five technology-intensive industries chosen for their overall importance in terms of U.S. corporate R&D, U.S. federal R&D, and global industry R&D. Besides these industries, a more diverse set of manufacturing firms and industries—including automotive, heavy equipment, consumer products, and food—also perform significant R&D activities in the U.S.
The life science segment includes diverse firms such as multinational pharmaceutical corporations, large medical device and instrument companies, and both large and small biotechnology firms. Though primarily engaged in human health care, firms in this segment are also involved in animal health and agricultural biosciences, and many operate in multiple areas.
Over the past 20 years, information and communication technologies (ICT) have been a key innovation enabler in many domains and have dramatically changed social behavior around the globe. In the past decade, the fortunes of many ICT companies have evolved significantly.
The resources invested in aerospace, defense, and national security R&D continue to dominate U.S. federal funding and constitute an important part of overall global R&D. U.S. federally funded defense R&D will reach nearly $75 billion in 2012, exceeding every other country's total R&D except that of China, Japan, and Germany.
Industrial R&D in the energy sector comprises a broad portfolio of technologies, including fossil, nuclear, and renewable generation; smart grid or other transmission and distribution; and energy-efficiency technologies. Energy-related research sponsored by U.S. utilities, manufacturers, and technology providers will reach nearly $6.7 billion in 2012.
The development of new and advanced materials is often the driver for other industries, such as those involving semiconductors, composites, thin films and coatings, medical devices, chemical and environmental processes, energy systems, and biopharmaceutical products. R&D for these materials involves developing new characteristics, properties, processing capabilities, and entirely new chemical families.
About 18% of all R&D performed in the U.S. is basic research, with academia having the largest share (60%). For the past 50 years, academia has had the largest share of basic research work. However, in the past, industry and government researchers each had about a 10% larger share of this work than they do now.
The following long-term developments are shaping the global distribution of R&D. As noted throughout this report, the newly emerging economies are developing home-grown technologies that often rival—and sometimes exceed—those of established economies.
The media seem to be filled with two perspectives on China’s R&D capabilities: (1) comments on its technology accomplishments and (2) attempts to put those accomplishments into perspective. Indeed, China has accomplished much over the past decade.
Many people call this the Asian Century because of the rapid economic, population, and technology growth in this area and the trends forecast for the next several decades. Asia has the world's largest regional gross domestic product (GDP), with its share currently at about 38% and increasing at about 1% per year.
This year we again approached the global researcher community, as identified through recent science and engineering publications, armed with an improved survey and sampling methodology to further clarify the nature of global R&D activities from the perspectives of the researchers themselves.
The following Websites are good sources of information related to the global R&D enterprise. Much of the information in the 2012 Global R&D Funding Forecast was derived from these sources, which are certainly not all-inclusive.